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D25V apolipoprotein C-III variant causes dominant
hereditary systemic amyloidosis and confers
cardiovascular protective lipoprotein proﬁle
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P. Patrizia Mangione5,6, Frank Bridoux8, Alain Mange´9,10,11,12, Ahmet Dogan13,14, Jean-Michel Goujon15,
Marie Lhomme16, Carolane Dauteuille17, Miche`le Chabert4,17,18, Riccardo Porcari5, Christopher A. Waudby19,
Annalisa Relini20, Philippa J. Talmud21, Oleg Kovrov22, Gunilla Olivecrona22, Monica Stoppini6,
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Apolipoprotein C-III deﬁciency provides cardiovascular protection, but apolipoprotein C-III is not
known to be associated with human amyloidosis. Here we report a form of amyloidosis char-
acterized by renal insufﬁciency caused by a new apolipoprotein C-III variant, D25V. Despite their
uremic state, the D25V-carriers exhibit low triglyceride (TG) and apolipoprotein C-III levels, and
low very-low-density lipoprotein (VLDL)/high high-density lipoprotein (HDL) proﬁle. Amyloid
ﬁbrils comprise the D25V-variant only, showing that wild-type apolipoprotein C-III does not
contribute to amyloid deposition in vivo. The mutation profoundly impacts helical structure stability
of D25V-variant, which is remarkably ﬁbrillogenic under physiological conditions in vitro producing
typical amyloid ﬁbrils in its lipid-free form. D25V apolipoprotein C-III is a new human amyloido-
genic protein and the ﬁrst conferring cardioprotection even in the unfavourable context of renal
failure, extending the evidence for an important cardiovascular protective role of apolipoprotein
C-III deﬁciency. Thus, ﬁbrate therapy, which reduces hepatic APOC3 transcription, may delay
amyloid deposition in affected patients.
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T
here is growing evidence that apolipoprotein C-III
(apoC-III), a small exchangeable apolipoprotein carried
in the circulation by VLDL and HDL1, is a master
regulator of plasma TG homeostasis and downregulation of its
expression has a cardiovasculo-protective effect2. ApoC-III
inhibits the activity of lipoprotein lipase (LPL), the enzyme
catalysing the ﬁrst and rate-limiting step of TG-rich lipoprotein
catabolism3, and also impairs uptake of TG-rich lipoprotein-
remnants by the low-density lipoprotein (LDL)-receptor
(LDL-R), increasing remnant residence time in the circulation4.
ApoC-III is a glycosylated apolipoprotein composed of 79 amino
acids, synthesized mainly in the liver, and existing in three
isoforms, apoC-III0, apoC-III1 and apoC-III2 with, respectively, 0,
1 and 2 residues of sialic acid per molecule, but little is known
about sialylation of apoC-III in disease states. Heterozygosity for
the rare null allele of APOC3, R19X, has been associated with high
levels of plasma HDL cholesterol (HDL-C), low levels of plasma
TG and reduced incidence of ischaemic cardiovascular disease
(CVD) in the Amish population5. Subsequently, genome-wide
association studies also identiﬁed the Arg19Stop variant in other
population isolates with a strong atheroprotective phenotype6.
More importantly, a recent general population-based study
conﬁrmed the association of APOC3 deﬁciency with an
atheroprotective lipid proﬁle and clinical protection against
ischaemic CVD7,8.
In its lipid-bound state, apoC-III is composed of six
amphipathic a-helices, the structural motif shared by all
exchangeable apolipoproteins that confers their structural
stability9. Conversely, apolipoproteins in lipid-free form have
lower conformational stability and some, such as native and/or
variants of apoA-I (ref. 10), apoA-II (ref. 11) and apoA-IV
(ref. 12), are prone to self-assembly in vitro and in vivo as
amyloid ﬁbrils. Recombinant wild-type apoC-III forms insoluble
aggregates with cross-b structure in vitro, reminiscent but not
typical of amyloid ﬁbrils13. Amyloid ﬁbril formation is associated
with a wide variety of diseases, and the hereditary monogenic
forms of human amyloidoses, although rare, provide unique
insight into mechanisms of protein misfolding and ﬁbrillogenesis
as recently highlighted by the discovery of the amyloidogenic
variant of b2-microglobulin14.
Here we report a French family with severe renal amyloidosis
and hypotriglyceridemia, both caused by a novel D25V apoC-III
variant. Remarkably, this variant induced a favourable cardio-
vascular lipoprotein proﬁle, even in the context of chronic kidney
disease (CKD). The D25V protein is highly ﬁbrillogenic in its
lipid-free state, and forms amyloid ﬁbrils under physiological
conditions in vitro. This study provides new insights into the
genetics of apoC-III and into VLDL and HDL metabolism in
health and disease, illustrating the increasing importance of
apoC-III in diverse biological processes.
Results
Patients. The proband (III.3 in Fig. 1a) presented at age 51 years
with sicca syndrome and hypertension. Two years later, he was
diagnosed with CKD; his serum creatinine level was 1.9mg dl 1
with modest proteinuria (40mg dl 1). Salivary gland and renal
biopsies showed amyloid deposits. A search for an underlying
monoclonal gammopathy was negative, and plasma concentra-
tions of serum amyloid A protein (SAA) and C-reactive protein
were in the normal range. The proband reached end-stage
renal disease (ESRD) aged 56 years and received a cadaveric
kidney transplant uneventfully. 123I-labelled serum amyloid P
component (SAP) scintigraphy, undertaken just before renal
transplantation in the proband III.3 (Fig. 1b) and in affected
member IV.3 (Fig. 1c), showed a small total body amyloid load in
the spleen and kidneys, at which point a fat aspirate demonstrated
extensive amyloid. Four years after renal transplantation, graft
function was normal (serum creatinine 0.88mg dl 1), without
detectable proteinuria. There was a strong family history of
amyloidosis (Fig. 1a) with all affected members suffering ﬁrst
from sicca syndrome and later developing mildly proteinuric
CKD. The proband’s grandmother (patient I.2) and aunt (patient
II.1) had suffered from sicca syndrome for many years before
developing systemic amyloidosis and had died aged 74 and
80 years, respectively. The proband’s father (patient II.3) had
presented with sicca syndrome aged 63 years, Raynaud
phenomenon, high blood pressure and diffuse pruritus. Salivary
gland, rectal and bronchial biopsies had all shown amyloid. He
reached ESRD aged 64 years. The proband’s younger sister
(patient III.5) had died aged 49 years of staphylococcal infection,
shortly after kidney transplantation. She had presented with
cardiac amyloidosis proven by biopsy 10 years earlier, associated
with CKD and mild proteinuria. She had reached ESRD and
started haemodialysis aged 40 years. She had also suffered from
sicca syndrome, Raynaud phenomenon, oesophageal reﬂux with
oesophagitis, diffuse pruritus and severe hypertension. Her two
children (patients IV.3 and IV.4) presented with sicca syndrome
at age 23 and 20 years, respectively, and both of them showed
amyloid deposits on salivary gland biopsies (Supplementary
Fig. 1). Both of them subsequently developed hypertension and
stage II CKD. The proband’s son (IV.1) suffered from sicca
syndrome aged 30 years and showed amyloid deposition on
salivary gland biopsy (Supplementary Fig. 1), but he had no
hypertension and his renal function was normal with a serum
creatinine level at 0.73mg dl 1 and no proteinuria. The
proband’s daughter (IV.2) was clinically asymptomatic, and had
no amyloid deposits on salivary gland biopsy.
Amyloid and hypotriglyceridemia in D25V apoC-III carriers.
An initial genetic screening for mutations in all genes recognized
until now to be linked to hereditary amyloidosis was negative (see
Methods for details). Based on the fact that affected patients with
amyloidosis also displayed hypotriglyceridemia and increased
plasma levels of HDL-C as compared with non-carriers in the
family (Table 1), we next screened several candidate genes
including the APOC3, APOC1, APOC2, APOC4, APOA4, APOA5
and APOE genes. The unique variant identiﬁed was a single-base
substitution (c.134A4T) in exon 3 of APOC3, encoding
replacement of the negatively charged aspartate residue at
position 25 of the mature apoC-III by a valine residue (D25V;
Fig. 1d). All D25V-carriers displayed a 30–50% decrease in
plasma apoC-III concentration (Table 1), and there was no cor-
relation between APOC3 promoter polymorphism genotypes and
plasma TG levels among family members (Fig. 1a).
Therefore, D25V apoC-III variant was uniquely found in family
members affected with amyloidosis, hypotriglyceridemia and
reduced apoC-III levels, and not in healthy normotriglycemic
family members, demonstrating the co-inheritance of this variant
with both the lipidemic and amyloidogenic phenotypic traits.
Histology and LMD/MS-proteomic analysis of amyloid deposits.
To establish that apoC-III D25V variant is the causative
amyloidogenic protein, we analysed amyloid deposits by
immunohistochemical staining, immunogold technology and
proteomic methodologies. Amyloid deposits were discovered in a
total of 17 diverse disease tissues from 6 different affected family
members through three generations (kidney, salivary glands,
heart, bowel, fat, and bronchia from III.3; kidney, salivary glands,
skin, heart, liver from III.5; salivary glands, kidney, skin, kidney,
bowel from II.3; salivary glands from IV.1, IV.3 and IV.4).
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All patients with sicca syndrome, the ﬁrst clinical symptom, were
carriers of D25V (II.3, III.3, III.5, IV.1, IV.3 and IV.4) and had
amyloid deposits in salivary gland biopsies. Conversely, clinically
non-affected individuals and non-carriers of D25V (III.1 and
IV.2) demonstrated no amyloid deposits on salivary gland
biospsies. In the proband III.3, all amyloid deposits observed in
salivary gland, digestive tract and kidney were Congo red positive
and immunoreactive with the anti-apoC-III antibody (Fig. 1e–g).
Moreover, extensive amyloid deposits were found around salivary
acini, in the interstitial matrix and in the walls of blood vessels,
and were associated with areas of ﬁbrosis and massive acinar
atrophy (Fig. 1e). Similar pathological ﬁndings in salivary glands
from younger affected family D25V-carriers (individuals IV.1,
IV.3 and IV.4) were found and are shown in Supplementary
Fig. 1. Therefore, this extensive amyloid accumulation associated
with gland atrophy could explain the sicca symptoms of mouth
reported by the patients. Renal histology from affected proband
III.3 at an advanced stage of renal insufﬁciency showed diffuse
amyloid deposition in the renal cortex that mostly affected the
vascular compartment with abundant amyloid deposits in the
walls of renal arterioles leading to lumen obliteration (Fig. 1g,h).
Deposits were also observed in the glomeruli with prominent
mesangial distribution, within the renal interstitium, and in the
peritubular basement membranes with tubular atrophy. Amyloid
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Figure 1 | Apolipoprotein C-III amyloidosis in a French family. (a) Pedigree showing three generations of transmission of the ApoC3 D25V variant with
systemic amyloidosis and decreased plasma triglyceride levels: APOC3 mutation present; clinical syndrome; ApoC-III amyloid conﬁrmed
histologically; decreased plasma triglyceride levels; no clinical syndrome, no amyloid on histology, absence of APOC3 mutation, no
hypotriglyceridemia. APOC3 haplotypes distribution of C-482T and T-455C polymorphisms is shown. D25Vþ/ , heterozygous for the apoC-III
amyloidogenic variant; D25V/ , absence of apoC-III mutation. (b,c) Serial anterior and posterior planar whole-body 123I- SAP scan. The scans from III.3
in b and IV.3 in c show a congested liver and amyloid in the spleen and kidneys. (d) Partial sequence chromatograms of APOC3 exon 3. (e) Amyloid
deposits in salivary glands from proband III.3. (f) Amyloid deposits in the duodenum from proband III.3 predominate in the submucosa around the vessels
and around Brenner’s glands. There are also amyloid deposits grouped in small clods within the intestinal villi. (g) Abundant vascular, moderate glomerular
and interstitial amyloid deposits in kidney from proband III.3. For each tissue in e–g, left panels show the Congo red staining, scale bar, 100mm; middle
panels show the Congo red-stained section viewed under polarized light, scale bar, 100mm; right panels show the immunoﬂuorescence with anti-apoC-III
antibody; scale bar, 100mm. (h) Left panel: amyloid deposits in the kidney are observed in the mesangium and the glomerular arteriole (arrow) (Jones
staining, scale bar, 100mm); middle and right panels: electron micrograph of amyloid ﬁbrils on immunogold staining with anti-apoC-III antibody, scale bar,
500 and 200 nm, respectively).
Table 1 | Plasma TG, HDL-C and APOC-III levels.
II.3 III.1 III.3 III.4 III.5 IV.1 IV.2 IV.3 IV.4
TG (g l 1) 0.30 1.80 0.31 1.38 0.44 0.34 0.86 0.35 0.50
HDL-C (g l 1) ND 0.35 0.71 0.57 0.79 0.59 ND 0.69 0.83
ApoC-III (mg l 1) ND 54.0 17.7 ND ND ND 44.2 18.8 34.4
apoC-III, apolipoprotein C-III; HDL-C, high-density lipoprotein-cholesterol; ND, not determined; TG, triglyceride.
II.3, III.1, III.3, III.4, III.5, IV.1, IV.2, IV.3, IV.4—refers to individuals in Fig. 1a.
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P component co-localized with the above-mentioned deposits,
and vascular, glomerular, tubular and interstitial amyloid deposits
were positively and speciﬁcally immunoreactive with apoC-III
antibody (Fig. 1g). Electron micrographs of the kidney specimen
from III.3 showed numerous non-branched and randomly
arranged deposits with a ﬁbrillar appearance, measuring 7–10 nm
in diameter, typical of amyloid (Fig. 1h). Immunoelectron
microscopic analysis subsequently showed that these renal
ﬁbrillar aggregates were speciﬁcally labelled by gold-conjugated
anti-apoC-III antibody (Fig. 1h). Therefore, our histologic
analysis, in conjunction with 123I-SAP scintigraphy, clearly
established the correlation between the clinical symptoms of
D25V-carriers (sicca syndrome and renal failure) and the
presence of amyloid in the respective tissues. In all 11 affected
tissues from 6 D25V-carriers over three generations, the
anti-apoC-III antibody consistently and speciﬁcally bound to all
Congo red-staining amyloid areas, whereas there was no binding
of antibodies against the other known amyloid ﬁbril proteins.
Moreover, the fact that anti-apoC-III antibody directly bound to
the ﬁbrillar aggregates conﬁrms at the ultrastructural level the
diagnosis of apoC-III amyloidosis.
In addition to immunoﬂuorescence and immunogold staining,
amyloid subtyping was also conﬁrmed by laser microdissection/
mass spectrometry (LMD/MS)-based proteomics on three
different tissues: digestive tract and heart from proband III.3,
and salivary glands from individual IV.3, with several amyloid
deposits microdissected per tissue (Fig. 2a,b and Supplementary
Table 1). In all proteomes, only the variant apoC-III containing
Valine 25 was invariably found in the diverse amyloid deposits
along with SAP and apoE, with no trace of the corresponding
wild-type apoC-III peptide (Fig. 2c). In the amyloid proteomes of
the digestive tract and salivary glands, wild-type apoA-IV and
apoA-I proteins were variably present, whereas both proteins
were absent in heart proteome (Fig. 2a,b and Supplementary
Table 1). These ﬁndings are in agreement with a number of
studies showing the presence of apoA-I and A-IV in various
amyloid deposits, irrespective of the nature of the amyloidogenic
protein15. The concordance between the amyloid proteomes from
different tissues of three D25V-carriers of this family, and the fact
that no other amyloid-associated proteins were found in the heart
except the mutated apoC-III clearly demonstrated that the
mutated apoC-III was the amyloid ﬁbril protein. Importantly,
neither peptides representing the D25V or the wild-type apoC-III
have been identiﬁed in the amyloid proteomes from over
5,000 patients with different types of systemic amyloidosis15,
clearly indicating that apoC-III is not a protein commonly
co-deposited in amyloid aggregates. Therefore, the D25V variant
was speciﬁcally found in this kindred for the ﬁrst time,
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Figure 2 | Proteomic analysis of amyloid plaques. Proteomic analyses of amyloid plaques from heart (a) and digestive tract (b) biopsy specimens of
patient III.3 showing the most abundant proteins found. In both amyloid proteomes, the variant apoC-III protein was identiﬁed along with the apolipoprotein
E and the serum amyloid P component. (c) ApoC-III tryptic peptide coverage: the two top lines represent the wild-type apoC-III sequence with the
20 amino-acid signal peptide and the mutant D25V (p. D45V) apoC-III sequence, respectively, and the two bottom lines represent the apoC-III peptides
identiﬁed from the amyloid plaques from the heart and digestive tract, respectively. All amyloid plaques contained only the mutated apoC-III peptide with
the valine at position 45 (corresponding to position 25 of the mature protein) and not the corresponding apoC-III wild-type peptide with the aspartate
residue.
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and histologic and proteomic analyses were consistent with the
genetic ﬁndings.
MS analysis of apoC-III from D25V-HDLs. To determine the
relative amounts of wild-type and mutant apoC-III as well as
the proportions of apoC-III isoforms in HDL2 and HDL3, MS
was carried out in these lipoproteins from hypotriglyceridemic
D25V carriers III.3, IV.3 and IV.4 and normotriglyceridemic
non-D25V-carrier III.4. The resulting MS proﬁles showed
that D25V-carriers exhibited a double peak for apoC-III1 and
apoC-III2 isoforms (only the proﬁle of individual IV.3 is
presented), whereas the non-carrier of D25V had a normal proﬁle
(Fig. 3a). The measured mass difference of 15.5 Da between
the two signals is in agreement with the difference between the
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Figure 3 | MS characterization of wild-type and D25V apoC-III isoforms in HDL2 and HDL3. (a) MS analysis of apoC-III isoforms from HDL2/HDL3.
Representative graphs of apoC-III isoforms from D25V carrier IV.3 and non-carrier III.4 are shown. Three apoC-III isoforms are commonly referred to as
apoC-III0, apoC-III1 and apoC-III2, where the index represents the number of sialic acid residues in each isoform. The subscript lower case letter indicates
the absence of glycans (apoC-III0a) or the presence of a GalNAc-Gal disaccharide (apoC-III0c), respectively. The arrow points to the peak corresponding to
the D25V variant of apoC-III isoforms with a reduced mass of 15,500Da (apoC-III1: 9,406.11; apoC-III2: 9,708.90) in comparison to the wild-type apoC-III
isoforms (apoC-III1: 9,421.61; apoC-III2: 9,714.40). The variant apoC-III1 and apoC-III2 isoforms are detected only in D25V-carriers. (b) Higher magniﬁcation
of apoC-III1 from the D25V-carrier IV.3 and a non-carrier III.4. (c) Mass spectrometric identiﬁcation of apoC-III in HDL2/3 using LC-MS/MS sequencing.
The amino-acid sequences obtained using MS/MS are in bold. Speciﬁc wild-type or mutated peptides are in red. The observed m/z of peptides (including
variable modiﬁcations) are listed in the table with their position in the apoC-III protein sequence.
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wild-type aspartate residue and the mutated valine residue
(15.9Da). A higher magniﬁcation of MS proﬁle is presented
in Fig. 3b. To conﬁrm that the additional peak observed in
D25V-carriers corresponds to the apoC-III variant, LC/MS-MS
sequencing was performed. As shown in Fig. 3c, both the tryptic
peptides containing the mutant Val25 and the wild-type Asp25 of
apoC-III isoforms were identiﬁed in heterozygous D25V-carriers,
whereas individual III.4 exhibited the wild-type apoC-III tryptic
peptide on HDL2/HDL3 subfractions.
Relative quantiﬁcation of each apoC-III isoforms was
performed in the three D25V-carriers (III.3, IV.3 and IV.4) and
compared with the non-carrier individual III.4. Data, summarized
in Table 2, show a twofold reduction of D25V-apoC-III compared
with its wild-type counterpart in all three affected patients with
amyloidosis. The levels of di-sialylated apoC-III were higher in
D25Vcarriers compared with the non-D25V-carrier, with a
corresponding decrease in mono- and non-sialylated apoC-III.
Lipoprotein studies. The lipoprotein proﬁles of III.3 and a
normolipidemic subject were substantially different. Interestingly,
VLDL was nearly absent, LDL was reduced and HDL was
massively increased in the proband’s plasma (Fig. 4a). A detailed
analysis of all lipoprotein constituents shows a ﬁvefold increase in
HDL2 (Table 3) but a lower apoC-III content in the proband’s
HDL2/HDL3 fractions (Supplementary Fig. 2). In addition,
HDL particles from III.3 were enriched in esteriﬁed and free
cholesterol, and in phospholipid, but depleted in TG and protein,
a composition typical of hyperalphalipoproteinemic HDL
(Table 4). The proﬁle of several lipid classes in the proband’s
HDL was altered (Table 5). Although the proband had CKD, his
HDL maintained an elevated cholesterol efﬂux capacity compared
with HDL of the normolipidemic control (Fig. 4b), whereas the
antioxidative activities of total HDL and small, dense HDL3c
were similar between the proband and the normolipidemic
control subject (Fig. 4c). The hypotriglyceridemia and
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Figure 4 | Lipoprotein studies. (a) Fast protein liquid chromatography (FPLC) size exclusion chromatogram of lipoproteins of III.3 in comparison to a
normolipidemic control subject. In each case 200ml of serum was analyzed using two GE Healthcare 10/300GL Superose 6 columns coupled in series,
equilibrated and eluted with a buffer containing 0.15M NaCl, 3mM EDTA, 0.04% sodium azide, pH 7.4 at 0.4mlmin 1. Triglyceride (TG) and total
cholesterol (TC) were determined in each fraction. (b) Cholesterol efﬂux capacity of HDL. THP-1 macrophages were cholesterol-loaded by incubation with
[3H]cholesterol-labelled acetylated LDL (1mCiml 1) for 24 h as detailed in the Methods. Cellular cholesterol efﬂux to HDL3c and total HDL from III.3 and
one normolipidemic control subject (15mgml 1 HDL-PL per well) was measured in serum-free medium for a 4 h chase period. The percentage of
cholesterol efﬂux was calculated as (medium cpm)/(medium cpmþ cell cpm) 100%. Speciﬁc cholesterol efﬂux was determined by subtracting
nonspeciﬁc cholesterol efﬂux occurring in the absence of cholesterol acceptors (HDL). (c) Antioxidative activity of HDL. The antioxidative capacity of
HDL3c and total HDL from III.3 and one normolipidemic control subject to inhibit LDL oxidation was assayed at a physiological HDL to LDL ratio.
HDL particles were compared on the basis of their total mass. Lipoprotein oxidation was induced by the azo-initiator 2,20-azo-bis-(2-amidinopropane)
hydrochloride (ﬁnal concentration 1mmol l 1). Oxidation was expressed as the concentration of lipid hydroperoxides with conjugated diene
structure in LDL.
Table 2 | Relative quantiﬁcation of apoC-III isoforms in D25V-carriers.
HDL2 HDL3
III.4 III.3 IV.3 IV.4 III.4 III.3 IV.3 IV.4
D25V/ D25Vþ/ D25Vþ/ D25Vþ/ D25V/ D25Vþ/ D25Vþ/ D25Vþ/
ApoC-III0 8.2 11.8 3.8 3.4 11.2 17.8 5.9 5.9
ApoC-III1 60.3 44.1 46.4 51.4 62.7 45.9 53.7 53.7
ApoC-III2 31.5 44.1 49.8 45.2 26.1 36.3 40.4 40.4
Ratio WT/D25V Apo-CIII1 — 2.4 2.1 2.4 — 1.6 1.7 2.0
Ratio WT/D25V Apo-CIII2 — 1.9 1.6 1.7 — 2.1 1.6 1.8
apoC-III, apolipoprotein C-III; WT, wild type.
Relative quantiﬁcation of each apoC-III isoform in three D25V-carriers (III.3, IV.3 and IV.4) in comparison with a healthy non-D25V-carrier (III.4). The ratio of apoC-III isoforms is modiﬁed in the
D25V-carriers and less D25V variant than wild-type apoC-III is present in HDL2/HDL3.
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hyperalphalipoproteinemia of apoC-III-D25V carriers confer an
atheroprotective proﬁle. This was corroborated by clinical data
(detailed imaging of coronary angiography, pulse arterial Doppler
ultrasound of the lower limbs and supra-aortic trunks, computed
tomography (CT) angiography of the aorta and iliac vessels)
establishing the absence of atheroma or vascular wall calciﬁcation,
whereas carotid intima-media thickness was normal in the pro-
band and his sister (III.5). Similarly, there was no record of
ischaemic CVD in D25V-patients I.2 or II.1, who died aged 74
and 82 years, respectively.
Analysis of structure, function and aggregation propensity.
Predictive analysis of the secondary structure of the apoC-III
polypeptide in its lipid-free state revealed that the D25V mutation
enhances both its beta-sheet content and aggregation propensity
(Fig. 5a,b). Although wild-type and D25V apoC-III initially
showed similar circular dichroic spectra, the mutation appears to
cause a transition towards prominent beta-sheet content
(Fig. 5c,d) associated with rapid formation of aggregates (Fig. 6a),
which were shown to increase the thioﬂavin T ﬂuorescence16,
the typical signature of amyloid ﬁbrils (Fig. 6b). Transmission
electron microscopy (Fig. 6c) and atomic force microscopy
(Fig. 6d) conﬁrmed the presence of ﬁbrillar structures in the
D25V apoC-III aggregated material.
The effect of the mutation on the lipid binding was also carried
out using dimyristoylphosphatidylcholine (DMPC) multilamellar
vesicles17. Analysis of the binding curves based on the decrease in
turbidity at 325 nm showed that the time required to reduce by
50% the initial turbidity of the vesicles was 168.7±8.1 s for the
variant and 114.7±4.2 s for the wild-type, respectively (Fig. 7a),
suggesting that the mutation may cause a less efﬁcient lipid
binding similar to other apoC-III variants17. At the equilibrium,
Table 3 | Lipoprotein composition.
Protein TG TC PL Total (mgdl 1)
(mgdl 1) (%) (mgdl 1) (%) (mgdl 1) (%) (mgdl 1) (%)
Control
VLDL 12.55 (9.3) 87.80 (65.0) 8.55 (6.3) 26.26 (19.4) 135.16
IDL 4.56 (20.6) 8.45 (38.1) 2.99 (13.5) 6.16 (27.8) 22.16
LDL 82.90 (35.2) 13.72 (7.2) 39.13 (20.4) 71.47 (37.3) 207.22
HDL2 22.79 (47.4) 2.86 (5.9) 8.19 (17.0) 14.26 (29.6) 48.09
HDL3 93.15 (63.1) 4.63 (3.1) 13.23 (9.0) 36.70 (24.9) 147.71
Proband (III.3)
VLDL 3.55 (11.4) 20.39 (65.7) 1.60 (5.1) 5.51 (17.8) 31.04
IDL 0.42 (4.9) 3.87 (45.9) 1.32 (15.7) 2.82 (33.4) 8.43
LDL 45.80 (31.7) 11.36 (7.9) 30.98 (21.4) 56.53 (39.1) 144.67
HDL2 117.22 (47.5) 5.02 (2.0) 40.19 (16.3) 84.63 (34.3) 247.06
HDL3 62.97 (56.6) 2.79 (2.5) 12.72 (11.4) 32.79 (29.5) 111.27
HDL, high-density lipoprotein; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein; PL, phospholipid; TC, total cholesterol; TG, triglyceride; VLDL, very-low-density lipoprotein.
Lipoproteins of the proband and of a control subject were isolated in parallel by sequential ultracentrifugation of serum (see Methods for details). All lipoprotein components were expressed in mg dl 1;
in parentheses are the percentages of components in each lipoprotein class.
Total is the sum of all constituents in each lipoprotein class.
Table 4 | Chemical composition (WT%) of HDL subpopulations.
Subjects HDL2b HDL2a HDL3a HDL3b HDL3c
CE (WT%) Proband 29.8 21.1 22.2 27.0 20.1
Control 26.0 23.3 21.6 13.1 12.6
FC (WT%) Proband 7.5 3.1 3.8 6.2 4.2
Control 6.5 4.1 3.3 4.5 1.7
PL (WT%) Proband 31.9 24.4 26.7 31.8 26.6
Control 32.0 25.8 25.6 24.9 16.9
TG (WT%) Proband 2.2 1.4 1.4 2.1 1.9
Control 3.1 2.5 1.9 2.0 1.0
Total protein (WT%) Proband 28.6 49.9 46.0 32.9 47.1
Control 32.4 44.4 47.6 55.4 67.9
CE, cholesteryl ester; FC, free cholesterol; HDL, high-density lipoprotein; PL, phospholipid; TG, triglyceride.
Data are shown as WT% of total HDL mass. The proband corresponds to individual III.3, and the control to one healthy normolipidemic subject.
Table 5 | Phospholipid and sphingolipid composition (WT%) of total HDL.
PC LPC SM Cer PE PI PS PG PA
Proband 78.6 0.59 18.1 0.211 1.2 1.1 0.030 0.008 0.013
Control 83.0 0.44 12.9 0.160 1.8 1.7 0.055 0.006 0.006
Cer, ceramide; LPC, lysophosphatidylcholine; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine;
SM, sphingomyelin.
Data are shown as WT% of total phospholipidsþ sphingolipids. The proband corresponds to individual III.3, and the control to one healthy normolipidemic subject.
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however, the variant was integrated in the vesicles as shown in the
native electrophoresis (inset, Fig. 7a). The native electrophoresis
revealed the strong propensity of the variant to self-aggregate in
its free form when it aggregated and precipitated at the site of
deposition (inset, Fig. 7a). Solubility of D25V apoC-III was,
however, rescued when the variant was integrated within
the vesicles. We have also investigated the effect of the
mutation on the well-known inhibition of LPL activity by
apoC-III (refs 3,18). The D25V apoC-III variant exhibited the
same inhibitory activity when compared with the wild-type
(Fig. 7b). It is worth noting that another mutation in position 25
(D25N, designed in silico), with the change in charge but
unmodiﬁed hydrophobicity, was as efﬁcient as the wild-type in
inhibiting LPL activity19.
We ﬁnally compared the 3D NMR structure of D25V apoC-III
with that of the wild-type counterpart already characterized
in the presence of SDS9. Two-dimensional 1H,15N NMR spectra
(Fig. 8a) showed small (o0.2 p.p.m., excluding residue 25) amide
chemical shift changes in the variant (Fig. 8b,c), which were
clustered within approximately one helical turn (3.6 residues) of
the mutation site. No chemical shift perturbations were
observed elsewhere in the sequence. The hydrodynamic radii of
wild-type and D25V apoC-III micellar complexes, recorded
by TRACT relaxation interference experiments, were virtually
indistinguishable (Fig. 8d). Moreover, there was no difference in
the helical conformation of residues 20–30 (Fig. 8e).
Discussion
Here we report a previously unappreciated, naturally occurring
APOC3 mutation6–8, which causes low levels of plasma TG and
apoC-III and a favourable lipoprotein proﬁle in a French kindred
affected with amyloidosis. Concordance between the APOC3
mutation and the presence of amyloid among members of this
kindred, coupled with identiﬁcation of D25V apoC-III within
amyloid ﬁbrils from numerous affected tissues and in vitro
demonstration of its amyloidogenicity, establishes that the D25V
variant also causes amyloidosis.
The phenotype of this new form of amyloidosis is mainly
characterized by onset with sicca syndrome as early as age 20
years, secondary to diffuse salivary gland deposits and progressive
renal insufﬁciency. We showed that these clinical symptoms are
caused by amyloid deposition in the respective tissues with
progressive and widespread amyloid accumulation within differ-
ent organs. In this novel form of renal amyloidosis, amyloid
deposition is characterized by prominent vascular involvement in
all compartments of the kidney and ischaemic glomerular lesions
that probably account for low-grade proteinuria and severe
hypertension. This clinical renal presentation contrasts those
described for Leu75Pro apoA1 amyloidosis20 and A-alpha chain
amyloidosis21, which typically manifests as a chronic tubulo-
interstitial nephritis with amyloid deposits restricted to the inner
medulla, or as proteinuria/nephrotic syndrome because of
massive glomerular amyloid deposition, respectively, ApoC-III
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measurements were performed in tapping mode with a Multimode Scanning Probe Microscope driven by a Nanoscope IV controller (Digital Instruments,
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should be added to the list of protein variants associated with
hereditary renal amyloidosis22, along with apoA-I (ref. 10, apoAII
(ref. 11), lysozyme23, ﬁbrinogen Aa-chain21 and gelsolin24. The
diagnosis of apoC-III amyloidosis may be suggested by
hypotriglyceridemia, present in all amyloidotic patients from
this kindred, a biological marker that is usually absent in patients
with other forms of hereditary renal amyloidosis.
Our in vitro studies clearly show that, despite the remarkable
differences in folding dynamics and kinetics of aggregation
between wild-type and D25V apoC-III in their lipid-free state,
their conformation and colloidal stability are similar in the lipid-
bound state. Wild-type apoC-III was recently reported to self-
aggregate into polymeric ordered structures with a peculiar
triangular geometry and a Mo¨bius strip conformation after 3 days
of shaking in physiological buffer. Although these structures do not
resemble the genuine amyloid ﬁbrils that we obtained under
physiological conditions with the D25V variant, it is worth noting
that aggregation of lipid-free wild-type apoC-III was preceded by a
gradual structural transition that resembles, in circular dichroism
(CD) spectroscopy, the conformation rapidly adopted by the D25V
variant. There is no evidence suggesting in vivo amyloidogenicity of
wild-type apoC-III and demonstration of aggregation in vitro does
not necessarily imply amyloidogenicity in vivo. Importantly, the
absence of wild-type apoC-III within the ex vivo amyloid ﬁbrils
from three patients in this kindred suggests that the wild-type
protein does not contribute to amyloid deposition even in the
presence of abundant D25V ﬁbrillar seeds, analogous to what we
have recently observed in patients with familial b2-microglobulin
amyloidosis14.
We hypothesize that the preferential incorporation of
D25V apoC-III into amyloid ﬁbrils is likely the main cause of
the imbalance in the ratio of wild-type/D25V apoC-III observed
within HDL particles. It will be worth investigating further in
appropriate cellular and/or animal models whether the secretion
of the variant may be partially impaired by the intracellular
quality control, similar to what we previously described for some
of the amyloidogenic variants of apoA-I (ref. 25), in which we
found an imbalance in the wild type/variant ratio.
D25V-carriers displayed a reduction in plasma and HDL
apoCIII concentration, hypotriglyceridemia associated with a
dramatic decrease in the number of VLDL particles, and a
concomitant massive increase in the larger HDL2 fraction. We
propose that these are indirect effects of the D25V variant
because of its very low concentration in plasma (and HDL
fractions) because of its preferential association with amyloid
ﬁbrils. The lower plasma apoC-III concentration in D25V-
carriers probably results in lack of inhibition of LPL and LDL-R.
As a consequence, VLDL-TG hydrolysis proceeds at high rate and
is followed by rapid uptake of VLDL-remnants (or intermediate
density lipoprotein (IDL) in Fig. 4b), provoking the drastic
decreases in VLDL and IDL of D25V-carriers (Fig. 4a,b). It has
been well established that surface lipids of VLDL, which
are liberated after LPL-mediated VLDL-TG hydrolysis, are
transferred to HDL by phospholipid transfer protein, resulting
in an increase in HDL size and particle number, as conﬁrmed
in mice deﬁcient either in LPL26 or in phospholipid
transfer protein27 and which lack HDL. Importantly, subjects
heterozygous for other loss-of-function APOC3 mutations
(K58E28 and R19X5,6) also present with hypotriglyceridemia
and increased plasma HDL.
The favourable lipid/lipoprotein proﬁle of D25V-carriers is
remarkable in the context of CKD and/or ESRD, pathological
conditions predisposing to premature atherosclerosis and major
ischaemic CVD events and commonly associated with an
unfavourable lipid proﬁle, an elevated plasma apoC-III concen-
tration and dysfunctional HDL carrying increased amounts
of apoCIII, serum amyloid A1 and lipoprotein-associated
phospholipase A2 (refs 29–31). Hypertriglyceridemia, often due
to accumulation of VLDL remnants/IDL in the circulation, is an
independent CVD risk factor32, and low plasma HDL is a second
independent CVD risk factor33. D25V-carriers displaying
hypotriglyceridemia and very high HDL2 are obviously lacking
in CVD risk factors. Moreover, their HDL is functional, as
evidenced by their normal antioxidant activity and cholesterol
efﬂux capacity possibly related to their enrichment in
sphingomyelin (SM). Furthermore, the lower apoC-III content
of HDL may contribute to atheroprotection as HDL particles
without apoC-III reduce monocyte adhesion to vascular
endothelial cells, whereas apoC-III-rich HDL do not, suggesting
that apoC-III may have additional proatherogenic effects on
vascular endothelial cells34. Thus, the pathologic amyloidogenic
properties of D25V apoC-III unexpectedly confer a favourable
cardioprotective lipoprotein proﬁle indirectly, most probably
through lowering of plasma apoC-III concentration, extending
the evidence for an important antiatherogenic role of APOC3
deﬁciency in ESRD patients.
As reducing the amyloid ﬁbril precursor protein concentration
is known to slow amyloid formation and improve prognosis
among patients with a variety of systemic amyloidoses, and as
PPARa agonists (ﬁbrates) signiﬁcantly reduce hepatic APOC3
transcription35,36, we postulate that ﬁbrate therapy may have
therapeutic potential for treatment of this new form of
amyloidosis. Because the safety and side-effect proﬁles of
ﬁbrates are well known, it might be reasonable to prescribe
ﬁbrates to the affected individuals from this kindred in an attempt
to slow down amyloid formation. If successful, this therapy could
represent an alternative to the gene silencing approach currently
under evaluation in other systemic amyloidoses37.
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(a) Lipid binding of ApoC-III was monitored by decrease in turbidity at
325 nm of DMPC vesicles mixed with recombinant wild-type or D25V
ApoC-III at a lipid/protein ratio of 2:1 (w/w) over 900 s at 30 C. The
binding curves shown are representative of three independent experiments
and expressed as percentage of the initial absorbance of the vesicles at
325 nm. The time required to reduce by 50% the initial signal at 325 nm
(t50%) is given as mean±s.d. of three replicates. Inset, native gel
electrophoresis shows the shift in mobility of both proteins after formation
of the vesicles with DMPC. Lanes: wild-type apoC-III alone (1) and with
DMPC (2); marker (3); D25V apoC-III alone (4) and with DMPC (5).
Marker for electrophoretic mobility is a ﬁvefold diluted plasma (see
Methods for details) in which the bands corresponding to the major plasma
protein components are highlighted: albumin (I), a-1 antitrypsin (II),
haptoglobin (III), transferrin (IV), ﬁbrinogen (V) and g-globulin (VI). The
arrow indicates the site of deposition of the samples where clearly the
apoC-III variant precipitated. Negative and positive gel polarities indicate
the direction of the electrophoretic run. (b) Inhibition of LPL activity was
determined keeping constant the incubation time and measuring the free
fatty acid release at different concentrations of the two apoC-III isoforms.
Data plotted as mean±s.d. of three independent experiments.
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Methods
Patients. The study was carried out in accordance with the Declaration of
Helsinki, and was approved by the University of Marseille Institutional Review
Board. All authors vouch for the completeness and accuracy of the analyses and
results. Oral and written informed consents were obtained from all participants,
including the transfer of biopsy material outside of France.
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Figure 8 | NMR spectroscopy. (a) 1H,15N-Heteronuclear single quantum coherence (HSQC) spectra of wild-type (WT, blue) and D25V (red) apoC-III.
Residue assignments of the variant were based on the Gangabadage9 assignment of the wild-type protein, using a nuclear overhauser effect spectroscopy
(NOESY)-HSQC spectrum (120ms mixing time) to reassign perturbed residues around the mutation site. Large chemical shift changes from the WT are
highlighted with arrows. (b) Amide chemical shift differences between WT and D25V apoC-III, calculated as the weighted combination DdNH¼ (DdH2 þ
(DdN/ 5)2)1/2. An asterisk (*) highlights the position of residue 25. (c) Amide chemical shift differences projected onto the WT NMR structure (pdb2jq3)
according to the indicated colour scale. Grey areas indicate unassigned residues or proline. (d) TRACT relaxation interference measurements34 of WTand
D25V apoC-III, determined by integration of the amide envelope and ﬁtting to single exponential decays. Fitted 15N relaxation rates±s.e. were
7.2±0.4 s 1 (WT) and 7.2±0.2 s 1 (D25V) in the a spin state, and 19.3±1.0 s 1 (WT) and 18.2±0.4 s 1 (D25V) in the b spin state, corresponding to
hydrodynamic radii values±s.e. of 20.3±0.6Å (WT) and 19.6±0.2Å (D25V). (e) 1H strips from the NOESY-HSQC spectrum of D25V apoC-III. Dashed
arrows highlight sequential NOEs from the Ha atom of residue i to the HN atom of residue iþ 1/iþ 3, which are diagnostic of a-helical structure.
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Genetic analysis. Genomic DNAs were extracted from peripheral blood samples,
using the QIAamp DNA mini kit (Qiagen). Coding and consensus splice site
regions of APOA1, APOA2, TTR, B2M, FGA, LYZ, GSN, SAA, APOE, APOC3,
APOC2, APOC1, APOC4, APOA4 and APOA5 genes were ampliﬁed by PCR
(AmpliTaq Gold; ABI, or Platinium Taq; Invitrogen), according to the
manufacturer’s instructions, in a DNA thermal cycler 9700 (Perkin-Elmer). The
primer sequences for APOC3 ampliﬁcation are listed in Supplementary Table 2.
The resulting PCR fragments were puriﬁed by QIAquick PCR Puriﬁcation kit
(Qiagen), and sequenced using the Big Dye terminator cycle sequencing kit (DNA
sequencing kit; Applied Biosystems) on an automatic genetic analyser (ABI PRISM
3100 genetic analyzer; Applied Biosystems)14. APOC3 polymorphims at positions
 455 (rs 2854116), and  482 (rs2854117) in the promoter region were
genotyped by direct sequencing. Mutation nomenclature was based on the APOC3
transcript reference (NCBI RefSeqcDNA accession number NM_000040.1), and
nucleotides were numbered according to the cDNA with þ 1 corresponding to the
A of ATG translation initiation codon according to the Human Genome Variation
Society guidelines, http://www.hgvs.org/mutnom//. Therefore, the apoC-III variant
is described as p.Asp45Val (with the signal peptide), whereas the mature protein is
designed as D25V.
Histology and immunohistochemistry. Amyloid was detected by Congo red
staining of formalin-ﬁxed wax-embedded biopsy sections14 (kidney, salivary
glands, heart, bowel, fat and bronchia from III.3; kidney, salivary glands, skin,
heart, liver from III.5; salivary glands, kidney, skin, kidney, bowel from II.3; salivary
glands from IV.1, IV.3, and IV.4). Amyloid typing was performed by indirect
immunoﬂuorescence and by immunoelectron microscopy14. For indirect
immunoﬂuorescence, 3 mm cryostat sections of frozen tissue were air dried,
incubated 1 h with primary goat anti-human ApoC3 polyclonal antibody (Abnova,
50mgml 1 in PBS), washed with PBS and stained with ﬂuorescent isothiocyanate-
conjugated donkey anti-goat antibody IgG, F(ab,)2 (Santa Cruz, 20 mgml 1 in
PBS). For the immunogold labelling procedure, thin sections (80 nm) were cut
from the routine (glutaraldehyde-ﬁxed, osmicated, Araldite embedded) electron
microscopic blocks, collected on nickel grids. Grids were ﬂoated on one drop of 5%
sodium metaperiodate (Sigma Chemical Co) in distilled water for 30min. Sections
were washed with distilled water three times and then saturated for 1 h with 3%
BSA in PBS in order to minimize nonspeciﬁc labelling. The grids were then
incubated overnight at 4 C with primary goat anti-human ApoC3 polyclonal
antibody (Abnova, 100mgml 1in PBS).
Sections were washed six times with PBS, incubated for 1 h with a rabbit
polyclonal biotin-conjugated anti-goat IgG secondary antibody (Clinisciences,
100mgml 1 in PBS) and 1 h with gold-labelled strepatavidin (Zymed Laboratories,
6 mgml 1 in PBS). Immunolabelled sections were contrasted using uranyl acetate
and observed under a JEOL 1010 transmission electron microscope (Jeol Ltd).
In all cases, parallel control negative sections consisting of the absence of the
primary apoC-III antibody were performed, demonstrating the speciﬁcity of the
apoC-III antibody.
LMD and tandem MS-based proteomics. Congo red-stained sections from
salivary glands (IV.3), heart and digestive tract (III.3) were examined for the
presence of amyloid under ﬂuorescence (Leica, B/G/R ﬁlter cube). Positive areas
were microdissected into 0.5ml microcentrifuge tube caps containing 10mM Tris,
1mM EDTA, 0.002% Zwittergent 3–16 (Calbiochem) using a Leica DM6000B
Microdissection System (Leica). For each case, —two to four different micro-
dissections (60,000 mm2 each) were collected. Collected tissues were heated at 98 C
for 90min with occasional vortexing. Following 60min of sonication in a water-
bath, samples were digested overnight at 37 C with 1.5 ml of 1 mgml 1 trypsin
(Promega)15. The trypsin generated digests were reduced with dithiothreitol and
separated by nanoﬂow liquid chromatography-electrospray tandem mass
spectrometry using a ThermoFinnigan LTQ Orbitrap Hybrid Mass Spectrometer
(Thermo Electron) coupled to an Eksigent nanoLC-2D HPLC system (Eksigent).
A 0.25-m1 trap (Optimize Technologies) packed with Michrom Magic C-8 was
plumbed into a 10-port valve. A 75 mmB15 cm C-18 column was utilized for the
separation utilizing an organic gradient from 6 to 86% in 55min at 400 nlmin 1.
The Thermo-Fisher MS/MS raw data ﬁles were searched using three different
algorithms (Mascot, Sequest and X!Tandem) and the results assigned peptide and
protein probability scores. The results were then combined and displayed using
Scaffold (Proteome Software). All searches were conducted with variable
modiﬁcations and restricted to full trypsin-generated peptides allowing for two
missed cleavages. Peptide mass search tolerances were set to 10 p.p.m. and
fragment mass tolerance to 1.00Da. The human SwissProt database (24 July 2007)
was complemented with frequently observed contaminants (porcine trypsin and
human keratins). Protein identiﬁcations below the 90% conﬁdence level and those
with single peptide identiﬁcation were not considered
Lipid and lipoprotein analysis. Plasma levels of TGs and HDL-cholesterol were
measured in the non-fasting state using standard hospital biochemical assays.
Plasma apoC-III concentrations were measured by electro-immunodiffusion.
Lipoprotein classes were prepared by sequential ultracentrifugation of sera from the
proband III-3 and a control subject run in parallel. Sequential ultracentrifugations
were performed at 100,000g and 10 C to isolate VLDL, IDL and LDL (for 18 h, at
densities 1.006, 1.020 and 1.063 gml 1, respectively) and HDL (for 40 h, at density
1.21 gml 1) in an OPTIMA XL 100K Beckman ultracentrifuge38. After extensive
dialysis of all lipoproteins against PBS containing/0.3mM EDTA, their protein
contents were measured with the Bio-Rad DC Protein assay kit II (Bio-Rad), and
their TG, total cholesterol and phospholipid with commercial kits (DiaSys). HDL
apolipoproteins were analysed by 15% SDS–PAGE under non-reducing conditions
to distinguish the apoA-II homodimer (17 kDa) from apo Cs38, and stained with
Coomassie Brilliant Blue G 250. Puriﬁed human apoA-I and apoA-II, as major
HDL apolipoproteins, were run as standards (4 mg per lane) in the gel. For apoC-III
detection, proteins were transferred to a nitrocellulose membrane and
immunoblotted with rabbit anti-human apoC-III antibody (1 mgml 1 in PBS,
Abnova) and secondary ECL anti-rabbit IgG-HRP-Linked speciﬁc whole antibody
(5,000-fold diluted in PBS, GE Healthcare). Puriﬁed human apoC-III (4 mg per
lane) was added as standard in the western blotting. Protein bands were visualized
with ECL Western Blotting Detection Reagent (GE Healthcare). Standard human
apoA-I, apoA-II and apoC-III were puriﬁed from delipidated HDL by preparative
isoelectric focusing with a pH gradient 4–6.
Fractionation of HDL subpopulations. HDL subpopulations were isolated
from plasma (3ml) by single step, isopycnic non-denaturing density gradient
ultracentrifugation in a Beckman SW41 Ti rotor at 40,000 r.p.m. for 44 h in a
Beckman XL70 ultracentrifuge at 15 C by a slight modiﬁcation of the method
of Chapman et al.39,40. After centrifugation, each gradient was fractionated
in predeﬁned volumes from the meniscus downwards with an Eppendorf
precision pipette into 11 fractions corresponding to very-low-density lipoprotein
and intermediate-density lipoprotein (VLDLþ IDL; 800 ml, do1.019 gml 1),
LDL (5 subfractions, 800ml each, LDL1, d¼ 1.019–1.023 gml 1;
LDL2, d¼ 1.023–1.029 gml 1; LDL3, d¼ 1.029–1.039 gml 1; LDL4,
d¼ 1.039–1.050 gml 1 and LDL5, d¼ 1.050–1.063 gml 1) and HDL.
Five major HDL subclasses were isolated, that is, large, light HDL2b (1,200 ml,
d¼ 1.063–1.087 gml 1) and HDL2a (800 ml, d¼ 1.088–1.110 gml 1), and small,
dense HDL3a (d¼ 1.110–1.129 gml 1), HDL3b (800 ml, d¼ 1.129–1.154 gml 1)
and HDL3c (800 ml, d¼ 1.154–1.170 gml 1). The validity and reproducibility of
this density gradient procedure, which facilitates preparative fractionation of HDL
particle subspecies in a non-denaturated, native state, have been extensively
documented39–41. All HDL subclasses isolated by this procedure are essentially
albumin free (o1% of total protein, that is, o0.05mg dl 1)42. Lipoproteins were
extensively dialysed (3 cycles of at least 8 h) against PBS pH 7.4 at 4 C in the dark,
stored at 4 C and used within 8 days.
Phosphosphingolipidome analysis. For the phosphosphingolipidome analysis,
HDL subpopulations (30 mg phospholipid mass determined using a commercially
available assay) were added to 4ml of cold CHCl3/acidiﬁed CH3OH (5:2 (v/v))
containing seven internal lipid standards (4mg of phosphatidylcholine d9 32:0,
100 ng of phosphatidylinositol (PI) 25:0, 80 ng of phosphatidylethanolamine, 25:0,
80 ng of phosphatidic acid 25:0, 40 ng of phosphatidylserine 25:0, 20 ng, of
phosphatidylglycerol 25:0 and 20 ng of ceramide 17:0; Avanti Polar Lipids)43.
A blank and a control sample were extracted in parallel with each batch to ensure
for quality control. K4EDTA (200mM) solution was added (1:5 (v/v)) and the
mixture was vortexed and centrifuged. The organic phase was dried under nitrogen
and lipids were reconstituted into isopropanol/hexane/water (10:5:2 (v/v)),
transferred into LC/MS vials, dried under nitrogen and resuspended in
isopropanol/hexane/water (10:5:2 (v/v)). Seven principal phospholipid (PL)
subclasses (phosphatidylcholine, lysophosphatidylcholine,
phosphatidylethanolamine, PI, phosphatidylglycerol, phosphatidylserine and
phosphatidic acid) and two principal sphingolipid (SL) subclasses, SM and
ceramide, which together comprise 4160 individual molecular lipid species and
account for 495% of total plasma PL and SM44 were assayed by LC/MS/MS.
Lipids were quantiﬁed using a QTrap 4000 mass spectrometer (AB Sciex), an
LC20AD HPLC system, and the Analyst 1.5 data acquisition system (AB Sciex).
Quantiﬁcation of PLs and SLs was performed in positive-ion mode, except for PI
species that were detected in negative-ion mode. Sample (4 ml) was injected onto a
Symmetry Shield RP8 3.5 mm, 2.1 50mm2 reverse phase column (Waters
Corporation) using a gradient from 85:15 to 91:9 (v/v) methanol/water
containing 5mM ammonium formate and 0.1% formic acid at a ﬂow rate of
0.1mlmin 1 for 30min. Lipid species were detected using multiple reaction
monitoring reﬂecting the head-group fragmentation of each lipid class and
quantiﬁed using calibration curves speciﬁc for the nine individual lipid classes with
up to 12 component fatty acid moieties; 23 calibration curves were generated in
non-diluted and tenfold diluted matrices to correct for matrix-induced ion
suppression effects. More abundant lipid species that displayed a nonlinear
response in non-diluted extracts were quantiﬁed from a 10- or 100-fold diluted
sample. An in-house developed script was used to compile data from the three
successive injections.
Cellular cholesterol efﬂux capacity of HDL. The cholesterol efﬂux capacity of
HDL was characterized in a human THP-1 monocytic cell system (ATCC)45. In
this assay, HDL particles were compared on the basis of their PL concentrations
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because PL was shown to represent the key component determining cholesterol
efﬂux capacity of HDL46. Brieﬂy, THP-1 monocytes were cultured on 24-well tissue
culture plates, grown in RPMI-1640 media with 10% FBS and differentiated into
macrophage-like cells with 50 ngml 1 phorbol 12-myristate 13-acetate for 48 h
and 37 C. The cells were washed and loaded for 24 h with [3H]cholesterol-labelled
acetylated LDL (1 mCiml 1) in serum-free RPMI-1640 culture medium
supplemented with 50mM glucose, 2mM glutamine, 0.2% BSA, 100 mgml 1
penicillin and 100 mgml 1 streptomycin (further abbreviated as RGGB) to allow
equilibration of cellular cholesterol pools. The labelling medium was removed and
human macrophages were then equilibrated in RGGB for an additional 16–24 h
period. Cellular cholesterol efﬂux to 15 mgml 1 HDL-PL was assayed in 300ml
serum-free medium for a 4-h chase period. Finally, culture media were harvested
and cleared of cellular debris by brief centrifugation. Cell radioactivity was
determined by extraction in hexane-isopropanol (3:2), evaporation of the solvent
under nitrogen and liquid scintillation counting (Wallac Trilux 1450 Microbeta,
Perkin Elmer). The percentage of cholesterol efﬂux was calculated as (medium
cpm)/ (medium cpmþ cell cpm) 100%. Speciﬁc cholesterol efﬂux was
determined by subtracting nonspeciﬁc cholesterol efﬂux occurring in the absence
of cholesterol acceptors.
Antioxidative activity of HDL. Antioxidative activity of HDL (ﬁnal concentration
of each, 10mg total mass per dl) was assessed at a physiological HDL to LDL ratio
towards reference LDL (d¼ 1.019–1.063 gml 1; ﬁnal concentration, 10mg dl 1
TC) isolated from one healthy normolipidemic control subject42,47,48. In this assay,
HDL particles were compared on the basis of their total mass concentrations
because both protein and lipid components were shown to contribute to the
capacity of HDL to inhibit LDL oxidation43,49,50. HDL subfractions were added to
LDL directly before oxidation. Lipoprotein oxidation was induced by an
azo-initiator 2,20-azo-bis-(2-amidinopropane) hydrochloride (ﬁnal concentration
1mmol l 1) as model of mild oxidation induced by free radicals in the arterial
intima42,47,48. Serum was used as a source of HDL for this assay to ensure intact
paraoxonase activity, which is inhibited by EDTA. Thereby, this assay employs
mild oxidative conditions and integrates the antioxidative activities of several HDL
components, that is, apoA-I, antioxidative enzymes and lipophilic low-molecular-
weight antioxidants43,49,50. Accumulation of conjugated dienes was measured as
the increment in absorbance at 234 nm. Absorbance kinetics values were corrected
for the absorbance of 2,20-azo-bis-(2-amidinopropane) hydrochloride itself run in
parallel as a blank. Three consecutive phases were identiﬁed, the lag, the
propagation and the decomposition phases for each curve and duration of the
propagation rate, oxidation rate in the propagation phase and amount of dienes
formed at the end of the propagation phase (maximal concentration of dienes)
were calculated as markers of antioxidative activity of HDL42,47,48.
MS analysis of apoC-III isoforms from HDL. Twenty micrograms of HDL
fraction was dissolved and acidiﬁed in 20 ml of 0.1% triﬂuoroacetic acid for 15min
with agitation. The protein was desalted using ZipTips C18 (Millipore) following
the manufacturer’s instructions and eluted with 20 ml of saturated matrix solution
of sinapinic acid in 50% acetonitrile and 0.5% (v/v) triﬂuoroacetic acid. The mass
spectrometric measurements were performed using a MALDI TOF/TOF 4800
Proteomics Analyzer mass spectrometer51. The MS spectra from m/z 8,000 to
10,000Da were acquired both in reﬂectron and in linear positive ion modes using
1,000 laser shots. For mass spectrometric identiﬁcation of ApoC-III in HDL2/3
using LC-MS/MS, 25mg of HDL fraction was dissolved into 500mM
triethylammonium bicarbonate, 1% SDS. Proteins were reduced with 10mM
dithiothreitol, alkylated with 20mM iodoacetamide and trypsin digested overnight.
The resulting peptides were cleaned up using OMIX C18 100 ml pipette tips
(Agilent), and lyophilized before being reconstituted for the LC-MS/MS analysis.
The peptides were separated using an Eksigent Ultra nano-LC HPLC system
coupled with an AB Sciex Triple TOF 5600 mass spectrometer. The LC separations
were performed using a Discovery Bio Wide Pore HPLC column (C18, 3 mm,
100 5mm2). The mobile phases used were 0.1% formic acid in water (A) and
100% acetonitrile with 0.1% formic acid (B). The gradient elution steps were
performed with a ﬂow rate of 5 ml min 1 as follows: 0–40% B for 106min, 40–80%
for 5min and then 80% B for an additional 5min. All data were acquired using
Analyst software (AB Sciex) in the data-dependent mode. Peptide proﬁling was
performed using a mass range of 350–1,600Da, followed by a MS/MS product ion
scan from 100 to 1,500Da. For each survey MS1 scan (accumulation time of
250ms), MS/MS spectra (accumulation time of 75ms per MS/MS) were obtained
for the 30 most abundant precursor ions. The protein identiﬁcation was performed
with the ProteinPilot Software 4.5.0 (AB Sciex). The MS/MS spectra obtained were
searched against the UniProt database (release 2014_03). The search parameters for
tryptic cleavage and accuracy are built-in functions of the software. Other data
analysis parameters were as follows: sample type: identiﬁcation; Cys-alkylation:
iodoacetamide; digestion: trypsin; instrument: TripleTOF 5600; special factor:
biological modiﬁcations; species: Homo sapiens; search effort: thorough ID.
Proteins comprising one or more peptides with a high conﬁdence score (95%)
and a low false discovery rate (estimated local false discovery rate of 1%) were
considered positively identiﬁed.
Radiolabelled SAP scintigraphy. Patients III.3 and IV.3 underwent 123I-labelled
SAP scintigraphy52 (http://www.amyloidosis.org.uk/diagnosis/sap-scintigraphy-3/).
Puriﬁed human SAP was labelled with 123I using the N-bromosuccinimide method.
Each patient received B100 mg SAP bearing 200MBq of 123I, corresponding to an
effective dose equivalent ofB3mSv. Thyroid uptake was blocked by oral ingestion
of potassium iodide for 2 days before and following isotope injection. Anterior and
posterior whole-body scintigraphy was performed 24 h after isotope administration
using a GE Healthcare-Discovery gamma-camera.
Expression and puriﬁcation of recombinant ApoC-III. ApoC-III was expressed
from a pET23b vector containing the full-length cDNA for human ApoC-III,
including the sequence encoding a C-terminal His6-tag preceded by Leu and
Glu additional residues17. pET23b/D25V was generated by using a QuikChange
site-directed mutagenesis kit (Stratagene). In a 50ml reaction, 50 ng of plasmid
DNA pET23b/ApoC-III was used as template and two synthetic oligonucleotide
primers, the forward primer (50-CCAAGACCGCCAAGGtTGCACTGAGCA
GCG-30) and the reverse primer (50-CGCTGCTCAGTGCAaCCTTGGCGGTCT
TGG-30) with the A-to-T base change complementary to opposite strands of the
vector, were extended by Pfu Turbo DNA polymerase (Stratagene). For PCR, there
was an initial cycle of 95 C for 30 s, followed by 12 cycles of 95 C for 30 s, 55 C
for 1min and 68 C for 2min. After DpnI digestion of the parental deoxyadenosine
methylase-methylated template, the synthesized mutated DNA was transformed
into E. coli XL1Blue supercompetent cells. Candidate clones were screened by
sequencing the ApoC3 insert on an ABI 377 prism DNA sequencer.
Prediction of beta aggregation propensity. The Garnier-Osguthorpe-Robson
(GOR) method version IV (ref. 53) was used to predict the beta propensity at the
mutation site. The aggregation propensities of wild-type and D25V ApoC-III were
predicted using the Zyggregator method54.
Fibrillogenesis. Fibrillogenesis experiments were performed in standard quartz
cells stirred at 1,500 r.p.m. (IKA magnetic stirrer) at 37 C using 100mM ApoC-III
isoforms in PBS, pH 7.4. Aggregation was carried out without seeds of preformed
ﬁbrils and the increase in turbidity at 350 nm was monitored. Thioﬂavin T
ﬂuorescence emission16 was measured at the end-point aggregation. Transmission
electron microscopy analysis was performed using protein samples stained with
2% (w/v) uranyl acetate using a CM120 microscope at 80 keV. Atomic force
microscopy analysis was carried out on 10 ml of ﬁbrillar sample incubated on a
freshly cleaved mica substrate for 5min, then rinsed and dried. Conformational
modiﬁcations during aggregation of apoC-III were monitored by far-UV CD.
Lipid-binding properties of apoC-III. Association of recombinant wild-type and
D25V apoC-III to DMPC multilamellar vesicles55, at a lipid-to-protein ratio of 2:1
(w/w), was followed by monitoring the decrease in turbidity of DMPC liposomes at
325 nm as a function of time at 30 C (ref. 17) in 0.01M Tris-HCl buffer pH 8.0
containing 150mM NaCl, 8.5% KBr, 0.01% NaN3 and 0.01% EDTA using a 1 cm
path length quartz cell in a Jasco V-650 spectrophotometer equipped with a Peltier
temperature controller. The lipid/protein association was expressed as percentage
of the turbidity of DMPC vesicles in the absence of apoC-III; the time required to
reduce the initial absorbance at 325 nm by 50% was determined from the curves to
compare the lipid-binding properties of the two apoC-III isoforms. Electrophoretic
mobility of wild-type and D25V apoC-III with and without DMPC was analysed
using 1% medium electroendosmosis agarose gel in 70mM barbiturate-sodium
barbiturate buffer, pH 8.6 containing 2mM calcium lactate. Samples (3 ml) were
applied to the gel including ﬁvefold diluted human plasma in 2% bromophenol
blue solution used as marker for protein electrophoretic mobility. Electrophoresis
was carried out in a 10 C water-thermostated chamber at 20V cm 1. Gel was
then ﬁxed for 15min in a 15% acetic acid solution containing 1% picric acid, dried
and stained with Coomassie Blue.
LPL inhibition. Bovine LPL catalytic activity, in the presence of apoC-III was
measured using an emulsion with the same composition as Intralipid 10%
(Fresenius-Kabi, Sweden) containing [3H]triolein substrate56. The incubation
medium contained 2% (v/v) of the emulsion, 0.1M NaCl, 60mgml 1 BSA, 0.15M
Tris-HCl, pH 8.5, and 16.7 Uml 1 heparin. The medium was pre-incubated with
or without each apoC-III sample for at least 10min before addition of bovine LPL
(0.25 mgml 1) in a ﬁnal 200ml mixture. After 30min incubation under agitation at
25 C, the reaction was stopped by adding 2ml of isopropanol, heptane and 1M
H2SO4 (40:48:3:1) and 0.5ml of water. Free fatty acids were extracted using
sequential centrifugations in glass tubes for 3min at 2,580g to separate each
mixture in two phases. After the ﬁrst centrifugation, 800ml of the upper phase was
transferred to other vials containing alkaline ethanol and then added with 3ml of
heptane before mixing and centrifuging again. After removal of the upper phase,
3ml of heptane were mixed to the lower phase, which was then centrifuged as
above. Supernatant was removed and 800 ml of the lower phase transferred to a vial
containing 2ml of scintillation liquid to count radioactivity and quantify the [3H]
free fatty acids (nmolmlmin 1). The LPL activity was then expressed as
percentage of the enzyme activity in the absence of apoC-III.
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NMR spectroscopy. NMR spectra were acquired for 0.5mM samples of wild-type
and D25V apoC-III (10mM sodium acetate (pH 5.0), 180mM SDS, 10% D2O) at
315K, using a 700-MHz BrukerAvance III spectrometer equipped with a TXI
cryoprobe, and processed with nmrPipe and CCPN Analysis.
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